Introduction:

Erythroblastosis fetalis (also known as hemolytic disease of the newborn) is a serious condition that can occur in newborns due to incompatibility between the mother’s and the baby’s blood types. This condition is primarily caused by an immune response during pregnancy, especially in women who have had multiple pregnancies. The immune system’s reaction to the fetus’s red blood cells leads to the destruction of these cells, which can cause severe anemia in the newborn. In this article, we will explore the mechanism behind this condition and the immune cells responsible for its development.

What is Erythroblastosis Fetalis?

Erythroblastosis fetalis occurs when there is an immune reaction against the fetal red blood cells. This condition most commonly arises when a Rh-negative mother carries a Rh-positive fetus. During pregnancy or at delivery, small amounts of fetal blood may enter the maternal bloodstream. If the mother is Rh-negative and has not previously been sensitized, her immune system will recognize the Rh-positive red blood cells as foreign and produce antibodies against them.

In subsequent pregnancies, if the mother is carrying another Rh-positive fetus, her immune system “remembers” the Rh antigen from the previous pregnancy. As a result, IgG antibodies are rapidly produced and cross the placenta, attacking the fetus’s red blood cells, leading to hemolysis (destruction of red blood cells) and causing conditions like anemia, jaundice, and in severe cases, fetal death.

The Role of Immune Cells in Erythroblastosis Fetalis

In erythroblastosis fetalis, the primary immune players are IgG-secreting memory cells. These memory cells are created during the first pregnancy when the mother’s immune system encounters the Rh-positive blood cells of the fetus. These memory cells “remember” the Rh antigen and are able to rapidly respond during subsequent pregnancies, producing IgG antibodies against Rh-positive cells.

The correct answer to the question “Haemolytic disease of the newborn called erythroblastosis fetalis commonly develops in mothers with repeated pregnancies owing to the activation of:” is:

1. IgG-secreting memory cells

This means that IgG antibodies produced by these memory cells play a crucial role in attacking the red blood cells of the fetus in later pregnancies, causing hemolytic disease.

Why is Erythroblastosis Fetalis Dangerous?

The danger in erythroblastosis fetalis arises from the fact that IgG antibodies can cross the placenta and attack the fetus’s red blood cells. The destruction of these cells leads to anemia, which reduces the ability of the fetus to carry oxygen, and can also cause jaundice after birth. In severe cases, it can result in heart failure or hydrops fetalis, a condition where the fetus accumulates fluid in its tissues, which can be fatal if not treated.

Prevention of Erythroblastosis Fetalis

The best way to prevent erythroblastosis fetalis is through the use of Rh immunoglobulin (RhIg), commonly known as RhoGAM. This treatment is given to Rh-negative mothers during pregnancy and after delivery of an Rh-positive baby. RhIg works by binding to any Rh-positive fetal blood cells that may have entered the mother’s bloodstream, preventing her immune system from recognizing them and developing a response. As a result, the mother’s immune system is not sensitized, and the risk of developing antibodies during future pregnancies is reduced.

Conclusion

Erythroblastosis fetalis is a serious and potentially life-threatening condition caused by an immune response to the Rh antigen. The activation of IgG-secreting memory cells during subsequent pregnancies is the key factor that leads to the condition. Early detection and prevention, particularly with the use of Rh immunoglobulin (RhoGAM), have greatly reduced the occurrence of this disease, helping protect both mothers and babies from its potentially harmful effects.

By understanding the role of IgG memory cells in this process, we can better appreciate the complexities of maternal-fetal immunology and the importance of timely medical intervention in preventing such conditions.